Upregulation of both mTOR and MEK signaling has been demonstrated in Lynch syndrome-associated colorectal cancer, and Niskakoski et al. recently reported frequent mutations in PIK3CA and absence of KRAS and BRAF mutations in ovarian cancers linked to Lynch syndrome [38, 39]. This evidence concerns the gene KRAS and ovarian carcinoma.